DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,446,865 | +4.3% | 78,383 | +0.9% | 2.27% | +8.6% |
| Q2 2023 | $18,653,280 | -4.0% | 77,722 | +0.8% | 2.09% | -11.7% |
| Q1 2023 | $19,428,503 | -3.4% | 77,085 | +1.7% | 2.36% | +16.8% |
| Q4 2022 | $20,116,182 | +3.4% | 75,790 | +0.7% | 2.02% | -0.8% |
| Q3 2022 | $19,448,000 | +1.6% | 75,295 | -0.3% | 2.04% | +7.1% |
| Q2 2022 | $19,143,000 | -14.2% | 75,507 | -0.7% | 1.90% | +6.2% |
| Q1 2022 | $22,310,000 | -10.9% | 76,056 | -0.0% | 1.79% | -17.0% |
| Q4 2021 | $25,033,000 | +7.3% | 76,085 | -0.7% | 2.16% | -2.9% |
| Q3 2021 | $23,327,000 | +12.1% | 76,622 | -1.2% | 2.22% | +24.4% |
| Q2 2021 | $20,816,000 | +20.5% | 77,568 | +1.1% | 1.79% | +22.5% |
| Q1 2021 | $17,271,000 | +0.9% | 76,732 | -0.4% | 1.46% | -3.2% |
| Q4 2020 | $17,114,000 | -30.0% | 77,041 | -32.2% | 1.51% | -38.6% |
| Q3 2020 | $24,459,000 | +22.2% | 113,588 | +0.4% | 2.46% | +7.9% |
| Q2 2020 | $20,008,000 | +28.2% | 113,148 | +0.3% | 2.28% | -6.9% |
| Q1 2020 | $15,609,000 | -12.1% | 112,774 | -2.5% | 2.45% | +28.0% |
| Q4 2019 | $17,757,000 | +6.0% | 115,694 | -0.2% | 1.91% | -4.0% |
| Q3 2019 | $16,748,000 | -49.3% | 115,956 | -49.9% | 1.99% | -46.3% |
| Q2 2019 | $33,057,000 | +5.3% | 231,298 | -2.7% | 3.71% | -1.3% |
| Q1 2019 | $31,384,000 | +27.5% | 237,722 | -0.4% | 3.76% | +24.2% |
| Q4 2018 | $24,613,000 | -5.8% | 238,684 | -0.7% | 3.03% | +6.6% |
| Q3 2018 | $26,123,000 | +6.7% | 240,411 | -3.1% | 2.84% | +0.1% |
| Q2 2018 | $24,482,000 | +0.2% | 248,098 | -0.5% | 2.84% | -1.7% |
| Q1 2018 | $24,425,000 | +3.6% | 249,466 | -1.8% | 2.88% | +21.7% |
| Q4 2017 | $23,572,000 | +7.0% | 253,952 | -1.1% | 2.37% | -0.5% |
| Q3 2017 | $22,023,000 | +3.0% | 256,739 | +1.3% | 2.38% | +7.2% |
| Q2 2017 | $21,383,000 | -1.9% | 253,379 | -0.6% | 2.22% | -3.6% |
| Q1 2017 | $21,797,000 | +10.3% | 254,851 | +0.4% | 2.31% | +5.1% |
| Q4 2016 | $19,766,000 | -0.9% | 253,931 | -0.2% | 2.20% | -5.5% |
| Q3 2016 | $19,940,000 | -21.0% | 254,366 | +1.8% | 2.32% | -27.6% |
| Q2 2016 | $25,247,000 | +6.3% | 249,970 | -0.2% | 3.21% | +11.4% |
| Q1 2016 | $23,749,000 | +1.5% | 250,360 | -0.6% | 2.88% | -2.6% |
| Q4 2015 | $23,403,000 | +7.9% | 251,969 | -1.0% | 2.96% | -2.5% |
| Q3 2015 | $21,681,000 | -0.3% | 254,436 | +0.2% | 3.04% | +14.9% |
| Q2 2015 | $21,742,000 | +0.8% | 254,024 | -0.0% | 2.64% | +1.7% |
| Q1 2015 | $21,570,000 | +1.7% | 254,060 | +2.7% | 2.60% | +6.0% |
| Q4 2014 | $21,210,000 | +14.1% | 247,467 | +1.2% | 2.45% | +3.6% |
| Q3 2014 | $18,584,000 | -1.5% | 244,592 | +2.0% | 2.36% | +2.7% |
| Q2 2014 | $18,876,000 | +7.2% | 239,761 | +2.2% | 2.30% | +1.9% |
| Q1 2014 | $17,600,000 | -5.7% | 234,668 | -2.9% | 2.26% | -8.8% |
| Q4 2013 | $18,660,000 | +11.9% | 241,716 | +0.5% | 2.47% | +3.1% |
| Q3 2013 | $16,677,000 | +13.4% | 240,586 | +3.6% | 2.40% | +14.0% |
| Q2 2013 | $14,701,000 | – | 232,243 | – | 2.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |